AtriCure, Inc.

ATRC

AtriCure, Inc.

ATRC

Insider Sentiment (TTM):

Last Purchase:2024-05-30Last Sale:2026-05-20Shares Purchased (TTM):0Shares Sold (TTM):29,133

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:48,341,965Shares Outstanding:48,334,000Institutional Ownership Pct.:100.02%

Earnings Market Reaction:

Filing Date:2026-07-27Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	168	146	167	148	118	100	123	130	106	65	84	81
Accounts Receivable Net Current	80	71	67	63	66	63	60	55	56	55	53	52
Short Term Investments	-	-	-	-	-	-	0	0	8	41	53	52
Inventory Net	84	81	78	79	76	75	75	77	74	72	68	62
Prepaid Expense And Other Assets Current	14	15	10	11	11	13	9	7	10	12	9	6
Assets Current	346	314	323	301	271	251	268	269	253	245	266	253
Property Plant And Equipment And Finance Lease Rig…	42	40	39	40	41	41	42	44	42	42	42	41
Long Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Assets Noncurrent
Operating Lease Right Of Use Asset	6	6	7	7	7	7	6	6	4	4	4	4
Intangible Assets Net Excluding Goodwill	43	46	48	50	52	54	56	58	60	62	64	66
Goodwill	235	235	235	235	235	235	235	235	235	235	235	235
Other Assets Noncurrent	5	4	3	3	3	3	3	3	3	3	2	2
Assets	677	644	654	635	609	592	609	615	597	592	614	600
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	36	31	25	25	26	25	25	32	27	29	27	25
Accrued Liabilities Current	43	40	53	49	40	33	46	40	32	30	45	37
Other Liabilities Current	3	3	3	3	-	-	3	-	-	-	-	21
Liabilities Current	82	73	82	78	69	61	73	74	61	61	75	83
Long Term Debt Noncurrent	61	61	62	62	62	62	62	62	62	62	61	42
Finance Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	8	8
Long Term Debt And Capital Lease Obligations Curre…	-	-	-	-	-	-	3	-	-	-	3	-
Other Liabilities Noncurrent	7	7	7	7	1	1	1	1	1	1	1	1
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	3	3
Liabilities	160	152	162	159	144	137	148	150	135	135	148	137
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	920	905	905	891	878	863	864	851	841	827	824	812
Accumulated Other Comprehensive Income Loss Net Of…	0	0	1	1	1	-0	-1	-0	-1	-1	-1	-2
Retained Earnings Accumulated Deficit	-404	-413	-413	-415	-415	-409	-402	-386	-378	-370	-357	-347
Stockholders Equity	516	492	492	477	464	455	461	465	462	456	466	463
Liabilities And Stockholders Equity	677	644	654	635	609	592	609	615	597	592	614	600
Allowance For Doubtful Accounts Receivable Current	1	1	1	1	1	1	1	0	0	0	1	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	90	90	90	90	90	90	90	90	90	90	90	90
Common Stock Shares Issued	51	51	50	50	50	49	49	49	49	48	48	47
Shares Outstanding	51	51	50	50	50	49	49	49	49	48	48	47

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.21%	7.75%	25.10%	-	-	-	-	-	-	-	-	-
2025	9.36%	4.98%	-2.17%	7.20%	3.70%	5.78%	6.10%	20.12%	14.58%	-7.81%	-12.82%	-18.84%
2024	4.37%	3.24%	8.78%	17.94%	34.54%	33.47%	2.61%	-11.80%	10.45%	-15.68%	-23.52%	-26.67%
2023	-	-	-	-	-	-	15.04%	1.42%	-8.37%	10.48%	-19.74%	-36.16%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.22	4.29	3.96	3.87	3.94	4.11	3.65	3.62	4.13	4.00	3.57	3.06
Quick Ratio	3.02	2.97	2.87	2.71	2.67	2.67	2.49	2.49	2.77	2.63	2.55	2.24
Working Capital	263.62M	240.50M	241.00M	223.27M	202.41M	190.26M	194.40M	194.86M	191.63M	183.97M	191.68M	170.18M
Leverage & Debt
Debt to Equity	0.31	0.31	0.33	0.33	0.31	0.30	0.32	0.32	0.29	0.30	0.32	0.30
Interest Coverage TTM	2.29	-0.51	-1.61	-4.54	-5.66	-5.70	-6.25	-5.06	-5.08	-4.57	-3.85	-3.31
Debt Ratio	0.24	0.24	0.25	0.25	0.24	0.23	0.24	0.24	0.23	0.23	0.24	0.23
Efficiency & Turnover
Asset Turnover TTM	0.89	0.89	0.85	0.83	0.83	0.81	0.76	0.74	0.72	0.71	0.67	0.64
Days Sales Outstanding TTM	46.77	44.50	43.36	41.51	44.38	45.10	44.26	43.40	44.11	44.45	43.51	44.58
Receivables Turnover TTM	7.80	8.20	8.42	8.79	8.22	8.09	8.25	8.41	8.27	8.21	8.39	8.19
Per Share Metrics
Diluted EPS TTM	0.22	-0.09	-0.24	-0.60	-0.76	-0.81	-0.95	-0.83	-0.86	-0.80	-0.66	-0.53
Free Cash Flow Per Share TTM	1.09	1.11	1.01	0.69	0.53	0.24	0.02	-0.02	-0.42	-0.53	-0.16	-0.28
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	76.30%	75.61%	74.98%	74.87%	74.71%	74.76%	74.69%	74.79%	74.84%	75.26%	75.23%	75.03%
Operating Profit Margin TTM	2.26%	-0.54%	-1.77%	-5.11%	-6.82%	-7.30%	-8.60%	-7.63%	-8.10%	-7.67%	-6.68%	-5.82%
Net Profit Margin TTM	1.85%	-0.83%	-2.14%	-5.55%	-7.27%	-7.95%	-9.61%	-8.70%	-9.33%	-8.98%	-7.62%	-6.52%
Growth Metrics
Net Revenue Growth (1Y)	13.94%	15.01%	14.88%	15.80%	16.28%	15.79%	16.55%	17.56%	17.57%	18.70%	20.84%	20.65%
Net Income Growth (1Y)	-129.02%	-87.97%	-74.39%	-26.07%	-9.38%	2.54%	46.85%	56.81%	43.11%	-1.40%	-34.49%	-55.71%
EPS Growth (1Y)	-128.46%	-88.20%	-74.81%	-27.33%	-10.92%	1.08%	44.80%	54.50%	41.14%	-2.69%	-35.30%	-56.27%
Valuation Metrics
P/E TTM	129.05	-300.23	-165.01	-58.71	-43.01	-40.05	-32.11	-33.94	-26.62	-38.17	-54.30	-81.91
P/B TTM	2.64	2.80	3.84	3.54	3.37	3.36	3.11	2.84	2.31	3.11	3.55	4.39
P/S TTM	2.39	2.50	3.53	3.26	3.13	3.18	3.08	2.95	2.48	3.43	4.14	5.34
Market Cap	1.36B	1.38B	1.89B	1.69B	1.56B	1.53B	1.44B	1.32B	1.07B	1.42B	1.65B	2.03B
Enterprise Value	1.25B	1.29B	1.78B	1.60B	1.51B	1.49B	1.38B	1.25B	1.02B	1.42B	1.63B	1.99B
Calculated Values
Free Cash Flow TTM	53.11M	53.64M	48.28M	33.00M	25.29M	11.33M	745.00K	-1.15M	-19.66M	-24.72M	-7.51M	-12.88M
Net Debt	-106.79M	-85.17M	-105.56M	-86.00M	-55.93M	-38.02M	-58.05M	-68.47M	-44.17M	-3.10M	-21.18M	-38.45M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-20Sale

Owner: Prange, Karen

Title: -

Shares: 3,000

Price/Share: $28.65

Value: $85,950.00

Shares Owned: 26,373

Relationship: Director

Ownership: Direct

2026-05-15Sale

Owner: Doraiswamy, Vinayak

Title: Chief Scientific Officer

Shares: 5,000

Price/Share: $28.13

Value: $140,650.00

Shares Owned: 91,875

Relationship: Officer

Ownership: Direct

2026-03-12Sale

Owner: Doraiswamy, Vinayak

Title: Chief Scientific Officer

Shares: 5,000

Price/Share: $29.83

Value: $149,150.00

Shares Owned: 96,875

Relationship: Officer

Ownership: Direct

2025-11-26Sale

Owner: Noznesky, Justin J

Title: Chief Mktg & Strategy Officer

Shares: 5,166

Price/Share: $37.29

Value: $192,640.14

Shares Owned: 78,798

Relationship: Officer

Ownership: Direct

2025-11-25Sale

Owner: Wehrwein, Sven

Title: -

Shares: 4,967

Price/Share: $38.00

Value: $188,746.00

Shares Owned: 34,374

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-20	Prange, Karen	Director	-	Direct	Sale	3,000	28.65	$85,950.00	26,373	4
2026-05-15	Doraiswamy, Vinayak	Officer	Chief Scientific Officer	Direct	Sale	5,000	28.13	$140,650.00	91,875	4
2026-03-12	Doraiswamy, Vinayak	Officer	Chief Scientific Officer	Direct	Sale	5,000	29.83	$149,150.00	96,875	4
2025-11-26	Noznesky, Justin J	Officer	Chief Mktg & Strategy Officer	Direct	Sale	5,166	37.29	$192,640.14	78,798	4
2025-11-25	Wehrwein, Sven	Director	-	Direct	Sale	4,967	38.00	$188,746.00	34,374	4
2025-11-21	Yuen, Maggie	Director	-	Direct	Sale	3,000	35.72	$107,160.00	11,371	4
2025-09-12	Noznesky, Justin J	Officer	Chief Mktg & Strategy Officer	Direct	Sale	3,000	36.30	$108,900.00	83,964	4
2025-08-22	Wehrwein, Sven	Director	-	Direct	Sale	5,000	37.00	$185,000.00	34,374	4
2025-08-19	Wehrwein, Sven	Director	-	Direct	Sale	5,000	36.00	$180,000.00	34,374	4
2025-08-06	Groves, Regina E	Director	-	Direct	Sale	2,452	36.82	$90,282.64	33,715	4
2025-08-05	Doraiswamy, Vinayak	Officer	Chief Scientific Officer	Direct	Sale	2,500	36.58	$91,450.00	71,872	4
2025-05-28	Doraiswamy, Vinayak	Officer	Chief Scientific Officer	Direct	Sale	2,500	33.44	$83,600.00	73,550	4
2025-03-05	Prange, Karen	Director	-	Direct	Sale	6,100	38.12	$232,532.00	17,828	4
2024-08-15	Yuen, Maggie	Director	-	Direct	Sale	3,500	24.07	$84,245.00	8,970	4
2024-05-30	Privitera, Salvatore	Officer	Chief Technical Officer	Direct	Purchase	5,000	22.25	$111,250.00	103,290	4
2024-05-01	Noznesky, Justin J	Officer	Chief Mktg & Strategy Officer	Direct	Sale	1,500	24.09	$36,135.00	71,284	4
2024-04-01	Noznesky, Justin J	Officer	Chief Mktg & Strategy Officer	Direct	Sale	1,500	30.39	$45,585.00	72,784	4
2024-03-18	Dahlquist, Karl S.	Officer	Chief Legal Officer	Direct	Sale	1,885	32.16	$60,621.60	50,954	4
2024-03-12	Noznesky, Justin J	Officer	Chief Mktg & Strategy Officer	Direct	Sale	1,500	36.72	$55,080.00	74,284	4
2024-03-05	Dahlquist, Karl S.	Officer	Chief Legal Officer	Direct	Sale	8,231	37.36	$307,510.16	52,839	4
2023-11-01	Dahlquist, Karl S.	Officer	Chief Legal Officer	Direct	Sale	1,248	34.43	$42,968.64	30,789	4
2023-07-26	Dahlquist, Karl S.	Officer	Chief Legal Officer	Direct	Sale	3,417	57.09	$195,076.53	32,037	4
2023-06-08	Prange, Karen	Director	-	Direct	Sale	713	47.89	$34,145.57	16,140	4
2023-06-06	Dahlquist, Karl S.	Officer	Chief Legal Officer	Direct	Sale	1,422	47.03	$66,876.66	34,897	4
2023-05-26	Yuen, Maggie	Director	-	Direct	Sale	4,313	47.04	$202,883.52	4,682	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

100.02%

Inst. Shares: 48,341,965

Shares Outstanding: 48,334,000

2025-12-31

96.55%

Inst. Shares: 46,102,078

Shares Outstanding: 47,750,000

2025-09-30

95.77%

Inst. Shares: 45,893,801

Shares Outstanding: 47,920,000

2025-06-30

97.17%

Inst. Shares: 46,368,560

Shares Outstanding: 47,721,000

2025-03-31

100.68%

Inst. Shares: 47,715,947

Shares Outstanding: 47,393,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	48,341,965	48,334,000	100.02%
2025-12-31	46,102,078	47,750,000	96.55%
2025-09-30	45,893,801	47,920,000	95.77%
2025-06-30	46,368,560	47,721,000	97.17%
2025-03-31	47,715,947	47,393,000	100.68%
2024-12-31	44,307,265	46,965,000	94.34%
2024-09-30	46,975,713	47,105,000	99.73%
2024-06-30	48,238,833	46,909,000	102.83%
2024-03-31	45,353,442	46,719,000	97.08%
2023-12-31	42,699,861	46,309,000	92.21%
2023-09-30	40,405,360	46,411,000	87.06%
2023-06-30	40,493,962	46,266,000	87.52%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

AtriCure, Inc. (ATRC) — SEC Financial Statements & Analysis

AtriCure, Inc. (ATRC) is a surgical & medical instruments & apparatus company, incorporated in DE. AtriCure, Inc. trades on Nasdaq as: ATRC. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), AtriCure, Inc. reported a 13.94% year-over-year revenue growth, a Gross Profit Margin of 76.30% (TTM), a Debt-to-Equity ratio of 0.31x, a Price-to-Sales (P/S) ratio of 2.39x (TTM), a Price-to-Book (P/B) ratio of 2.64x (TTM), at a market cap of $1.36B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 13.94%
Gross Profit Margin TTM: 76.30%
Debt To Equity: 0.31x
P/S TTM: 2.39x
P/B TTM: 2.64x
Market Cap: $1.36B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is AtriCure, Inc. in?

AtriCure, Inc. (ATRC) operates in the Surgical & Medical Instruments & Apparatus industry.

What is ATRC's market cap?

AtriCure, Inc. (ATRC) has a market capitalization of $1.36B as of 2026-06-30.

What is ATRC's P/E ratio?

AtriCure, Inc. (ATRC)'s trailing twelve month P/E ratio is 129.05x as of 2026-06-30.

What exchange does ATRC trade on?

AtriCure, Inc. (ATRC) trades on the Nasdaq.

Where is AtriCure, Inc. incorporated?

AtriCure, Inc. is incorporated in DE.

AtriCure, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

AtriCure, Inc. (ATRC) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.
Main Street's price.

AtriCure, Inc. (ATRC) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.